FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Stock Option

(Right

to Buy)

\$ 255.69

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instru	ction 1(b).			111	.vcs	umem	t Con	ірапу	710	. 01 1	740									
	pe Response			2 Icens	or No	ama ar	nd Tiel	er or T	Fradi	ina Sv	mbol		15	5. Rela	ntionship	of Reportir	ng Person(s)	to Issuer		
Name and Address of Reporting Person Seth Alpna					S. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH] 3. Date of Earliest Transaction (Month/Day/Year) 11/09/2020									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 614 MCKINLEY PLACE NE													Officer (give title below)Other (specify below)							
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person									
MINNEAPOLIS, MN 55413																				
(Cit	y)	(State)	(Zip)				Table	e I - No	on-D	erivat	ive S	ecuritie	s Acquir	red, D	isposed	of, or Bene	ficially Own	ied		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				2A. Deemed Execution Date, if r) any (Month/Day/Year)		Code (Instr		or Disposed of (D)			5. Amount of Owned Foll Transaction (Instr. 3 and		ed Follov action(s)	ving Reporte	6. Ownersl Form: Direct (I	of Be	Nature Indirect eneficial enership			
						Co	de	V	Amou		(A) or (D)	Price			,	or Indire (I) (Instr. 4)	ct (In	istr. 4)		
Common Stock			11/09/2020			N	M		1,89	8 A	\$ 17	79.84	4,037			D				
Common Stock			11/09/2020			N	1		3,12	5 A	\$ 12	25.05	7,162		D					
Common Stock			11/09/2020			S	5		1,35	8 1	\$ 30 (1		5,80	4			D			
Common Stock 11/09/20			11/09/2020			S	S		3,66	5 I	\$ 30 <u>(2</u>		2,13	;9			D			
Reminder:	Report on a s	separate line for each	h class of securities l	oeneficia	lly o	wned	directly	F	Pers in th	ons v	m ar	e not re		to re	spond	unless the	tion contain	ned S	EC 147	74 (9-02)
			Table II -	Derivat (e.g., pu										Owne	d					
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code		5. Nu of Deriv Secur Acqu (A) o Dispo	vative rities aired or cosed	6. Da Expir			xercisable and n Date		7. Title of Unde Securiti	Title and Amount 8. Pr Underlying Dericurities Secu		Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forn Deri Secu Dire or In	of vative rity: et (D) direct	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exerc	eisab		Expira Date	ation	Title	1	Amount or Number of Shares					
Stock Option (Right to Buy)	\$ 179.84	11/09/2020		M			1,898		(3)	1	10/25	5/2028	Comn		1,898	\$ 0	0		D	
Stock Option (Right to Buy)	\$ 125.05	11/09/2020		M		í	3,125		(3)	1	10/26	5/2027	Comn		3,125	\$ 0	0		D	

Common

Stock

1,507

1,507

D

10/29/2021 10/29/2030

Stock Option (Right to Buy) \$ 201.64

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Seth Alpna							
614 MCKINLEY PLACE NE	X						
MINNEAPOLIS, MN 55413							

Signatures

/s/ Brenda S. Furlow, attorney in fact for Seth Alpna pursuant to Power of Attorney previously filed	11/12/2020	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$305.72 to \$305.79, inclusive. The reporting person (1) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$306.84 to \$307.26, inclusive. The reporting person (2) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (3) Fully exercisable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

The undersigned hereby constitutes and appoints Brenda S. Furlow, James Hippel, Anna Weispfenning, Melodie R. Rose, Andrew Nick, Sarah Tucher or either of them acting alone, the undersigned's true and lawful attorneysin-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26th day of October, 2017.

/s/ Alpna Seth